Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
SmithKline Beecham (Export) Limited, commonly referred to as SmithKline Beecham, is a prominent player in the pharmaceutical industry, headquartered in Great Britain. Established in the late 20th century, the company has made significant strides in global health, focusing on the development and export of innovative healthcare solutions.
With a strong presence in Europe and other key international markets, SmithKline Beecham excels in areas such as prescription pharmaceuticals, vaccines, and consumer health products. Their unique portfolio includes cutting-edge treatments that address a variety of health conditions, setting them apart in a competitive landscape.
Recognised for their commitment to quality and innovation, SmithKline Beecham has achieved notable milestones, solidifying their market position as a trusted provider of healthcare products. Their dedication to improving patient outcomes continues to drive their success in the global marketplace.
+64 vs industry average
SmithKline Beecham (Export) Limited’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Business Services has below-average carbon intensity
The Business Services industry has reduced its overall emissions by 25% since 2018
No reported emissions data is available for SmithKline Beecham (Export) Limited yet.
SmithKline Beecham (Export) Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of GSK plc, and any climate commitments or emissions data would be cascaded from this parent organization.
GSK plc has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and commitments to renewable energy through the RE100 initiative. These initiatives aim to significantly reduce carbon emissions across their operations, although specific reduction targets for SmithKline Beecham (Export) Limited have not been detailed.
As a subsidiary, SmithKline Beecham (Export) Limited aligns with GSK plc's overarching climate strategy, which focuses on reducing Scope 1, 2, and 3 emissions. However, without specific emissions data or reduction targets available for SmithKline Beecham (Export) Limited, the company's individual climate impact remains unclear.
No climate goals have been disclosed for SmithKline Beecham (Export) Limited yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for SmithKline Beecham (Export) Limited yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more